The US Food and Drug Administration (FDA) has issued a partial clinical hold on the enrolment of new patients in Epizyme’s ongoing Phase I and II trials of tazemetostat to treat genetically defined solid tumours and hematologic malignancies.

The clinical hold is based on a safety report submitted by Epizyme to the FDA, detailing the condition of a paediatric patient with advanced poorly differentiated chordoma who developed a secondary T-cell lymphoma in the Phase I trial.

During the submission of the report, the patient had been on study for around 15 months and achieved a confirmed partial response.

"We are working expeditiously with clinical trial investigators and regulatory authorities to initiate the appropriate steps to resume enrolment."

Following the development of secondary malignancy, the patient has stopped taking tazemetostat and is currently being treated for T-cell lymphoma.

According to Epizyme, doses used in the Phase I trial are higher than the doses explored in the Phase II adult study, which is a very common approach used in the development of difficult-to-treat paediatric cancer drugs.

The company also noted that this is the only incident where a patient treated with tazemetostat developed secondary lymphoma under its clinical trial programme that has so far treated over 750 patients.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Epizyme president and CEO Robert Bazemore said: “Patient safety is of the utmost importance to Epizyme.

“We are working expeditiously with clinical trial investigators and regulatory authorities to initiate the appropriate steps to resume enrolment.

“Epizyme, along with our global investigator community, has been very encouraged by the clinical responses and tolerability of tazemetostat observed in paediatric and adult patients with hematological malignancies and solid tumours enrolled in our trials.”

Under the Phase I and II trials of tazemetostat, Epizyme aims to develop the EZH2 inhibitor as a monotherapy for the treatment of certain molecularly defined solid tumours, including epithelioid sarcoma and other INI1-negative tumours.

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now